Suraksha FY26 revenue rises 22.5%, dividend recommended
Suraksha Diagnostic Limited reported a 22.5% YoY increase in total revenue to INR3,136 million for FY26, with PAT growing 1.4% to INR314 million. The EBITDA margin for the year stood at 31.8%. The company served 1.37 million patients and expanded its network to 68 centers. The Board recommended a dividend of ₹0.50 per share and approved the re-appointment of auditors.
*this image is generated using AI for illustrative purposes only.
Suraksha Diagnostic Limited has reported its audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026. The company achieved a total revenue of INR3,136 million for FY26, registering a year-on-year growth of 22.5% compared to INR2,559 million in FY25. Profit after tax for the year stood at INR314 million, reflecting a 1.4% increase from the previous year. The Board of Directors recommended a dividend of ₹0.50 per equity share for FY26, subject to shareholder approval, with the record date fixed for Wednesday, 26 August 2026.
Q4 and FY26 Financial Performance
For the fourth quarter of FY26, the company reported a total revenue of INR822 million compared to INR659 million in Q4 FY25, a growth of 25%. EBITDA for Q4 FY26 stood at INR252 million compared to INR200 million in the same period last year, with the EBITDA margin remaining stable at 31%. PAT for the quarter was INR62 million, up from INR22 million in Q4 FY25. On a full-year basis, EBITDA increased by 15.8% year-on-year to INR986 million, while the EBITDA margin for FY26 was 31.8% compared to 33.8% in FY25.
| Metric | FY26 | FY25 |
|---|---|---|
| Total Revenue | INR3,136 million | INR2,559 million |
| EBITDA | INR986 million | INR851 million |
| EBITDA Margin | 31.8% | 33.8% |
| Profit After Tax | INR314 million | INR310 million |
Operational Highlights and Expansion
Suraksha served 1.37 million patients in FY26, executing 8.16 million clinical tests. The revenue per patient increased to INR2,264, driven by a shift towards specialized diagnostics and advanced radiology. Pathology contributed 48.85% of operational revenue, while radiology contributed 44.26%. The company expanded its network during the year, adding two hub centers, 11 spoke centers, and three centers under the PPP model, bringing the total count to 68 centers as of March 2026.
Management outlined the strategic focus for FY27, which includes expanding footprint across eastern and northeastern India. The company plans to establish three new hubs and eight asset-light spoke centers within West Bengal, and launch one specialized hub center each in Bihar, Tripura, and Jharkhand. The total planned capex for this rollout is around INR70 crores.
Corporate Actions
The board approved the notice convening the 21st Annual General Meeting (AGM), scheduled for Wednesday, 02 September 2026, via video conferencing. Additionally, the board approved the re-appointment of M/s. S Chhaparia & Associates as Cost Auditor for FY 2026-27 and appointed M/s. Suresh Surana & Associates LLP as the Internal Auditor for the financial year 2026-27. The text transcript of the earnings call held on 22 May 2026 is available on the company's website.
Historical Stock Returns for Suraksha Diagnostic
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.19% | -4.28% | -7.73% | -1.14% | -19.59% | -35.37% |
How will the planned INR 70 crore capex for FY27 impact the company's leverage ratios and free cash flow in the near term?
Can the shift towards specialized diagnostics and advanced radiology sustain the current revenue per patient growth amidst increasing competition?
What are the expected revenue contributions and break-even timelines for the new hubs planned for Bihar, Tripura, and Jharkhand?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
